Recent health news includes major pharmaceutical listings in Hong Kong, a White House report on food and chemical impacts on ...

Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Procurement Magazine takes a look back at the biggest news from across the industry over the last seven days, including SAP, ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish ...

Holy Moley Rocky! Pipsqueak pharmacy wins slam dunk verdict against Big Pharma—re: Ozempic and Wegovy?! Incredible story with ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...